Members of the Texas Drug Utilization Review (DUR) Board meet quarterly in Austin to promote safety through an increased review and awareness of outpatient prescribed drugs. Members recommend medical criteria, standards, and educational intervention methods used in Texas Medicaid. The board reviews and approves the therapeutic criteria for prospective and retrospective drug utilization as well as clinical prior authorization criteria. In addition, members also recommend drugs for inclusion in the Medicaid preferred drug list, considering the drug's clinical efficacy, safety, cost-effectiveness, and program benefits.
Please review the written and public testimony procedures prior to submitting information to board members.
By Regular/Overnight Mail
Texas Drug Utilization Review Board (MC-2250)
Texas Health and Human Services
4900 North Lamar Blvd.
Austin, TX 78751
By Email
This address is only for issues pertaining to the Texas DUR board. Messages received off-cycle or unrelated to the business of the board are not accepted.
News
November 20, 2020
Revision to Kalydeco Clinical Prior Authorization Begins Dec. 28
November 13, 2020
July 2020 Preferred Drug List Decisions Now Available
November 5, 2020
2021 Drug Utilization Review Board Schedule Available
November 5, 2020
Members Sought for the Drug Utilization Review Board
November 4, 2020
October 2020 Drug Utilization Review Board Meeting Summary
November 3, 2020
July 2020 Preferred Drug List Revised Oct. 30